-
摘要:目的
探讨分化差的胃神经内分泌肿瘤的临床病理特点和辅助治疗对预后的影响。
方法回顾性分析经根治性手术治疗的胃神经内分泌肿瘤124例，根据肿瘤分类标准对肿瘤进行分类、分级和分期，并进行随访，采用Kaplan-Meier法绘制生存曲线，Log rank检验进行单因素分析，Cox比例风险回归模型进行多因素分析。
结果胃神经内分泌瘤、胃神经内分泌癌和混合性腺神经内分泌癌的5年生存率分别为100%、52.4%和38.8%，多因素分析示淋巴结转移与否（P=0.030）和有无辅助治疗（P=0.017），尤其是顺铂联合依托泊苷方案（HR=0.051, P=0.015）是影响胃神经内分泌癌患者的独立预后因素；而淋巴结转移、远处转移、TNM分期和有无辅助治疗均不是混合性腺神经内分泌癌患者的独立预后因素。
结论胃神经内分泌癌患者的预后与淋巴结转移和有无辅助治疗有关，其辅助治疗可以考虑顺铂联合依托泊苷方案。
Abstract:ObjectiveTo explore the effects of clinicopathological features and adjuvant therapy on the prognosis of patients with poorly-differentiated gastric neuroendocrine tumors.
MethodsWe retrospectively analyzed 124 cases of gastric neuroendocrine tumors treated with radical surgery. The neoplasms were classified into different types, grades and stages according to the standard of classification. Follow-up was conducted. The survival curves were drawn by Kaplan-Meier method. Univariate analysis was performed by Log rank test and multivariate analysis was conducted by Cox proportional hazards model.
ResultsThe 5-year survival rates of gastric neuroendocrine tumor, gastric neuroendocrine carcinoma and gastric mixed adenoneuroendocrine carcinoma patients were 100%, 52.4% and 38.8%, respectively. Multivariate analysis showed that lymph node metastasis (P=0.030) and adjuvant therapy (P=0.017), especially cisplatin combined with etoposide regimen (HR=0.051, P=0.015) were independent prognostic factors for patients with gastric neuroendocrine carcinoma; while lymph node metastasis, distant metastasis, TNM stage and adjuvant therapy were not independent prognostic factors for patients with mixed neuroendocrine carcinoma.
ConclusionThe prognosis of patients with gastric neuroendocrine carcinoma is related to lymph node metastasis and adjuvant treatment, and cisplatin plus etoposide regimen is a reasonable choice for adjuvant treatment.
-
Key words:
- Gastric neuroendocrine neoplasm /
- Adjuvant chemotherapy /
- Prognosis
-
作者贡献张剑： 收集资料、分析数据、撰写论文臧凤琳： 病理阅片张家丽： 收集资料、论文修改张新伟： 论文修改
-
![]()
图 3 有无辅助治疗对TNM Ⅲ+Ⅳ胃MANEC患者生存的影响
Figure 3 Effect of adjuvant therapy on survival of patients with TNM Ⅲ+Ⅳ gastric MANEC
![]()
图 4 含铂化疗方案对不同Ki-67指数的NEC患者预后的影响
Figure 4 Effects of chemotherapy with platinum on prognosis of patients with different Ki-67 index
-
[1] Modlin IM, Shapiro MD, Kidd M. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors[J]. Hum Pathol, 2004, 35(12): 1440-51. doi: 10.1016/j.humpath.2004.09.018
[2] Rindi G, Arnold R, Bosman FT, et al. WHO Classification of Tumours of the Digestive System[M]. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC), 2010: 13-4.
[3] Cao LL, Lu J, Lin JX, et al. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database[J]. Eur J Surg Oncol, 2018, 44(10): 1628-33. doi: 10.1016/j.ejso.2018.01.082
[4] Yao JC, Hassan M, Phan A, et al. One hundred years after " carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States[J]. J Clin Oncol, 2008, 26(18): 3063-72. doi: 10.1200/JCO.2007.15.4377
[5] Xu X, Li J, Han X, et al. Clinical characteristics and prognostic factors of patients with gastric neuroendocrine carcinoma treated with radical surgery[J]. Chin Med J (Engl), 2014, 127(13): 2419-22. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhcmj201413004
[6] Liu DJ, Fu XL, Liu W, et al. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas[J]. World J Gastroenterol, 2017, 23(3): 516-24. doi: 10.3748/wjg.v23.i3.516
[7] Yin XN, Shen CY, Yin YQ, et al. Prognoses in patients with primary gastrointestinal neuroendocrine neoplasms based on the proposed new classification scheme[J]. Asia Pac J Clin Oncol, 2018, 14(2): e37-e44. doi: 10.1111/ajco.2018.14.issue-2
[8] Kim BS, Park YS, Yook JH, et al. Comparison of the prognostic values of the 2010 WHO classification, AJCC 7th edition, and ENETS classification of gastric neuroendocrine tumors[J]. Medicine (Baltimore), 2016, 95(30): e3977. doi: 10.1097/MD.0000000000003977
[9] Park JY, Ryu MH, Park YS, et al. Prognostic significance of neuroendocrine components in gastric carcinomas[J]. Eur J Cancer, 2014, 50(16): 2802-9. doi: 10.1016/j.ejca.2014.08.004
[10] Xie JW, Lu J, Lin JX, et al. Different long-term oncologic outcomes after radical surgical resection for neuroendocrine carcinoma and adenocarcinoma of the stomach[J]. Oncotarget, 2017, 8(34): 57495-504.
[11] Ishida M, Sekine S, Fukagawa T, et al. Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis.J]. Am J Surg Pathol, 2013, 37(7): 949-59.
[12] 陈洛海, 陈洁, 周志伟.胃肠道神经内分泌肿瘤治疗最新指南解读[J].中华胃肠外科杂志, 2016, 19(11): 1201-4. doi: 10.3760/cma.j.issn.1671-0274.2016.11.001 Chen LH, Chen J, Zhou ZW. Interpretation of the latest guidelines in the treatment of gastrointestinal neuroendocrine neoplasms[J]. Zhonghua Wei Chang Wai Ke Za Zhi, 2016, 19(11): 1201-4. doi: 10.3760/cma.j.issn.1671-0274.2016.11.001
[13] 徐海燕, 张志影, 任芳, 等.胃神经内分泌癌的临床病理特征及预后因素[J].世界华人消化杂志, 2014, 22(22): 3291-9. http://d.old.wanfangdata.com.cn/Conference/9476356 Xu HY, Zhang ZY, Ren F, et al. Clinicopathological characteristics and prognostic factors of gastric neuroendocrine carcinoma[J]. Shi Jie Hua Ren Xiao Hua Za Zhi, 2014, 22(22): 3291-9. http://d.old.wanfangdata.com.cn/Conference/9476356
[14] Xie JW, Sun YQ, Feng CY, et al. Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma[J]. Eur J Surg Oncol, 2016, 42(10): 1464-70. doi: 10.1016/j.ejso.2016.08.004
[15] 寇玉, 高业博, 马杰, 等.胃神经内分泌癌42例预后分析[J].中华胃肠外科杂志, 2013, 16(6): 570-3. doi: 10.3760/cma.j.issn.1671-0274.2013.06.018 Kou Y, Gao YB, Ma J, et al. Prognostic analysis of 42 patients with gastric neuroendocrine carcinoma[J]. Zhonghua Wei Chang Wai Ke Za Zhi, 2013, 16(6): 570-3. doi: 10.3760/cma.j.issn.1671-0274.2013.06.018
[16] 林晓琳, 许琦, 刘泽兵, 等.胃神经内分泌癌临床病理特征及预后相关因素[J].肿瘤, 2017, 37(10): 1079-85. doi: 10.3781/j.issn.1000-7431.2017.33.528 Lin XL, Xu Q, Liu ZB, et al. Clinicopathological characteristics and prognosis-srlated factors of gastric neuroendocrine carcinoma[J]. Zhong Liu, 2017, 37(10): 1079-85. doi: 10.3781/j.issn.1000-7431.2017.33.528
[17] Okita NT, Kato K, Takahari D, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma[J]. Gastric Cancer, 2011, 14(2): 161-5. doi: 10.1007/s10120-011-0025-5
[18] Coriat R, Walter T, Terris Bea. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement[J]. Oncologist, 2016, 21(10): 1191-9. doi: 10.1634/theoncologist.2015-0476
[19] Heetfeld M, Chougnet CN, Olsen IH, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms[J]. Endocr Relat Cancer, 2015, 22(4): 657-64. doi: 10.1530/ERC-15-0119
[20] Vélayoudom-Céphise FL, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous?[J]. Endocr Relat Cancer, 2013, 20(5): 649-57. doi: 10.1530/ERC-13-0027
[21] de Mestier L, Cros J, Neuzillet C, et al. Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms[J]. Neuroendocrinology, 2017, 105(4): 412-5. doi: 10.1159/000475527
下载:
计量
- 文章访问数: 1691
- HTML全文浏览量: 360
- PDF下载量: 546
